Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin/Etoposide/Radiotherapy + Docetaxel + Bevacizumab in Stage III NSCLC
NCT00334815Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2006
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jun 2006; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00334815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334815.